Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Genmab A/SNASDAQ: GMAB

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of $295M fell 30.2% year over year. Sequentially, it rose 454.6% from the prior quarter. Over 3 fiscal years it compounded at -48.4% a year.

Context

  • Net income amounted to 25.9% of revenue in FY2025, down 10.6 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 15 analysts of $774.08M (-19.7%) for the fiscal year ending Dec 2026, a step up from the -87.7% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$295M+454.6% QoQ
Last fiscal yearDec 2025
$963.76M-87.7% YoY
LTMJun 2026
$861.1M— YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.2%-50.7%-20.4 pp
1 year-87.7%-19.7%+68.0 pp
3-year CAGR-48.4%+18.6%+67.0 pp
5-year CAGR+11.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

Mixed currencies · from the cash flow

Latest · FY2025
963.76M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Net income amounts to 20.8% of revenue for GMAB, versus a peer median of 48.6%.
GMAB Competitors
Net Income for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BNTXBioNTech SELTM Jun 2026€1.71B EUR+348.2%—64.7%
INCYIncyte CorporationLTM Jun 2026$1.61B USD+85.1%+55.7%27.7%
GMABGenmab A/SLTM Jun 2026$861.1M USD—-48.4%20.8%
EXELExelixis, Inc.LTM Jul 2026$860.62M USD+42.9%+62.5%35.3%
RCUSArcus Biosciences, Inc.LTM Jun 2026$460M USD+54.4%+9.8%393.2%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$220.54M USD-44.5%-0.4%58.2%
ADCTADC Therapeutics S.A.LTM Mar 2026$136.99M USD-8.6%-3.2%173.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$88.87M USD-31.7%-6.3%—
MGNXMacroGenics, Inc.LTM Mar 2026$70.36M USD+26.1%-14.6%44.8%
CGENCompugen Ltd.LTM Dec 2025$35.34M USD——48.6%
LEGNLegend Biotech CorporationLTM Sep 2026$2.81M USD-98.7%-12.6%0.2%
Peer median (excluding GMAB) —+26.1%-1.8%48.6%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Net Income3.98B7.04B5.64B7.84B963.76M
Depreciation & Amortization248.99M362M293.62M413M71.06M
Deferred Income Tax(546M)0122M00
Stock-Based Compensation310M439M586M721M0
Change in Working Capital(770M)(1.93B)1.36B(1.6B)225.18M
Accounts Receivables(1.07B)(2.12B)797M(1.59B)(166.13M)
Inventory00(57M)(5M)(9.01M)
Accounts Payables304M283M622M0400.32M
Other Working Capital0(90M)000
Other Non-Cash Items(997.99M)(1.99B)(620.62M)388M(73.06M)
Operating Cash Flow2.23B3.91B7.38B7.77B1.19B
Capital Expenditures(252M)(317M)(376M)(187M)(37.03M)
Acquisitions (Net)709M2.44B0(12.25B)(7.22B)
Purchases of Investments(15.62B)(9.7B)(10.91B)(8.64B)(995.78M)
Sales of Investments14.91B7.25B10B11.28B2.62B
Other Investing Activities(709M)(2.44B)(10M)(117M)0
Investing Cash Flow(961M)(2.76B)(1.28B)(9.91B)(5.65B)
Debt Repayment(58M)(73M)(91M)(60M)5.23B
Common Stock Issued000023.02M
Common Stock Repurchased(447M)(908M)(564M)(3.99B)(430.34M)
Dividends Paid00000
Other Financing Activities85M192M49M129M(31.02M)
Financing Cash Flow(420M)(789M)(606M)(3.92B)4.79B
Effect of Forex Changes850M574M(518M)1.05B13.06M
Net Change in Cash1.7B936M4.97B(5.01B)345.33M
Free Cash Flow1.98B3.6B7B7.58B1.15B

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.